Sign in Sign up for free

Last updated: 18 May 2022 at 11:34pm EST

David Low Net Worth




The estimated Net Worth of David N. Low is at least $161 Thousand dollars as of 13 December 2019. Mr. Low owns over 300,000 units of ContraFect Corp stock worth over $85,893 and over the last 10 years he sold CFRX stock worth over $0. In addition, he makes $74,979 as Independent Director at ContraFect Corp.

Mr. Low CFRX stock SEC Form 4 insiders trading

David has made over 2 trades of the ContraFect Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 300,000 units of CFRX stock worth $129,000 on 13 December 2019.

The largest trade he's ever made was buying 300,000 units of ContraFect Corp stock on 13 December 2019 worth over $129,000. On average, David trades about 28,333 units every 73 days since 2015. As of 13 December 2019 he still owns at least 370,550 units of ContraFect Corp stock.

You can see the complete history of Mr. Low stock trades at the bottom of the page.





David Low biography

David N. Low Jr. serves as Independent Director of the Company. Mr. Low has worked as an investment banker since 1987, with broad investment and advisory experience in the life sciences, biotechnology and medical technology sectors. Since June 2017, Mr. Low has served as a partner at MTS Health Partners, a healthcare investment banking boutique. From 2002 to April 2017, Mr. Low was a member of Lazard’s Life Sciences Group as a Managing Director and Senior Advisor. Mr. Low has advised on major M&A transactions in the life sciences, biotechnology and medical technology sectors, and has worked with private and public companies to raise capital, including emerging growth companies. Prior to joining Lazard, Mr. Low was a Managing Director at JP Morgan Chase & Co. and a Senior Vice President at Lehman Brothers. Mr. Low serves on the board of directors of the Philharmonia Baroque Orchestra. Mr. Low holds an A.B. from Harvard College, where he graduated cum laude, an M.A. from the Johns Hopkins University School of Advanced International Studies and an M.B.A. from Yale University.

What is the salary of David Low?

As the Independent Director of ContraFect Corp, the total compensation of David Low at ContraFect Corp is $74,979. There are 10 executives at ContraFect Corp getting paid more, with Roger Pomerantz having the highest compensation of $1,875,610.



How old is David Low?

David Low is 61, he's been the Independent Director of ContraFect Corp since 2014. There are 8 older and 8 younger executives at ContraFect Corp. The oldest executive at ContraFect Corp is Sol Barer, 72, who is the Lead Independent Director.

What's David Low's mailing address?

David's mailing address filed with the SEC is C/O CONTRAFECT CORPORATION, 28 WELLS AVENUE, 3RD FLOOR, YONKERS, NY, 10701.

Insiders trading at ContraFect Corp

Over the last 10 years, insiders at ContraFect Corp have traded over $2,523,392 worth of ContraFect Corp stock and bought 525,578 units worth $426,359 . The most active insiders traders include Sol J Barer, Roger Pomerantz, and Industrial Co., Ltd Fosun. On average, ContraFect Corp executives and independent directors trade stock every 70 days with the average trade being worth of $16,159. The most recent stock trade was executed by Michael Messinger on 13 December 2019, trading 5,000 units of CFRX stock currently worth $1,850.



What does ContraFect Corp do?

we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba



What does ContraFect Corp's logo look like?

ContraFect Corp logo

Complete history of Mr. Low stock trades at ContraFect Corp

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
13 Dec 2019 CFRX ContraFect Corp David N. Low
Director
 Buy 300,000 $0.43 $129,000
13 Dec 2019
370,550 ↗
25 Jul 2017 CFRX ContraFect Corp David N. Low
Director
 Buy 40,000 $1.24 $49,600
25 Jul 2017
70,550 ↗


ContraFect Corp executives and stock owners

ContraFect Corp executives and other stock owners filed with the SEC include: